Cargando…
Percutaneous cryoablation for the treatment of extra‐abdominal desmoid tumors
BACKGROUND: Desmoid tumors are rare locally invasive, benign neoplasms that develop along aponeurotic structures. Current treatment is complicated by associated morbidity and high recurrence rates. METHODS: A retrospective, single‐institution review identified 23 patients (age: 16‐77) with extra‐abd...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790665/ https://www.ncbi.nlm.nih.gov/pubmed/31236956 http://dx.doi.org/10.1002/jso.25597 |
_version_ | 1783458819801612288 |
---|---|
author | Redifer Tremblay, Kaila Lea, William B. Neilson, John C. King, David M. Tutton, Sean M. |
author_facet | Redifer Tremblay, Kaila Lea, William B. Neilson, John C. King, David M. Tutton, Sean M. |
author_sort | Redifer Tremblay, Kaila |
collection | PubMed |
description | BACKGROUND: Desmoid tumors are rare locally invasive, benign neoplasms that develop along aponeurotic structures. Current treatment is complicated by associated morbidity and high recurrence rates. METHODS: A retrospective, single‐institution review identified 23 patients (age: 16‐77) with extra‐abdominal desmoid tumors who received CT‐guided percutaneous cryoablation as either a first‐line (61%) or salvage (39%) treatment in 30 sessions between 2014 and 2018. Median maximal lesion diameter was 69 mm (range: 11‐209). Intent was curative in 52% and palliative in 48%. Contrast‐enhanced cross‐sectional imaging was obtained before and after treatment in addition to routine clinical follow‐up. RESULTS: Technical success was achieved in all patients. The median follow‐up was 15.4 months (3.5‐43.4). Symptomatic improvement was demonstrated in 89% of patients. At 12 months, the average change in viable volume was −80% (range −100% to + 10%) and response by modified response evaluation criteria in solid tumors (mRECIST) was CR 36%, PR 36%, and SD 28% No rapid postablation growth or track seeding was observed. Four patients underwent repeat cryoablation for either residual or recurrent disease. Two patients sustained a major procedural complication consisting of significant neuropraxia. CONCLUSION: Cryoablation for desmoid tumors demonstrates a high degree of symptom improvement and local tumor control on early follow‐up imaging with relatively low morbidity. |
format | Online Article Text |
id | pubmed-6790665 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-67906652019-10-18 Percutaneous cryoablation for the treatment of extra‐abdominal desmoid tumors Redifer Tremblay, Kaila Lea, William B. Neilson, John C. King, David M. Tutton, Sean M. J Surg Oncol Research Articles BACKGROUND: Desmoid tumors are rare locally invasive, benign neoplasms that develop along aponeurotic structures. Current treatment is complicated by associated morbidity and high recurrence rates. METHODS: A retrospective, single‐institution review identified 23 patients (age: 16‐77) with extra‐abdominal desmoid tumors who received CT‐guided percutaneous cryoablation as either a first‐line (61%) or salvage (39%) treatment in 30 sessions between 2014 and 2018. Median maximal lesion diameter was 69 mm (range: 11‐209). Intent was curative in 52% and palliative in 48%. Contrast‐enhanced cross‐sectional imaging was obtained before and after treatment in addition to routine clinical follow‐up. RESULTS: Technical success was achieved in all patients. The median follow‐up was 15.4 months (3.5‐43.4). Symptomatic improvement was demonstrated in 89% of patients. At 12 months, the average change in viable volume was −80% (range −100% to + 10%) and response by modified response evaluation criteria in solid tumors (mRECIST) was CR 36%, PR 36%, and SD 28% No rapid postablation growth or track seeding was observed. Four patients underwent repeat cryoablation for either residual or recurrent disease. Two patients sustained a major procedural complication consisting of significant neuropraxia. CONCLUSION: Cryoablation for desmoid tumors demonstrates a high degree of symptom improvement and local tumor control on early follow‐up imaging with relatively low morbidity. John Wiley and Sons Inc. 2019-06-24 2019-09-01 /pmc/articles/PMC6790665/ /pubmed/31236956 http://dx.doi.org/10.1002/jso.25597 Text en © 2019 The Authors. Journal of Surgical Oncology Published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Research Articles Redifer Tremblay, Kaila Lea, William B. Neilson, John C. King, David M. Tutton, Sean M. Percutaneous cryoablation for the treatment of extra‐abdominal desmoid tumors |
title | Percutaneous cryoablation for the treatment of extra‐abdominal desmoid tumors |
title_full | Percutaneous cryoablation for the treatment of extra‐abdominal desmoid tumors |
title_fullStr | Percutaneous cryoablation for the treatment of extra‐abdominal desmoid tumors |
title_full_unstemmed | Percutaneous cryoablation for the treatment of extra‐abdominal desmoid tumors |
title_short | Percutaneous cryoablation for the treatment of extra‐abdominal desmoid tumors |
title_sort | percutaneous cryoablation for the treatment of extra‐abdominal desmoid tumors |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790665/ https://www.ncbi.nlm.nih.gov/pubmed/31236956 http://dx.doi.org/10.1002/jso.25597 |
work_keys_str_mv | AT redifertremblaykaila percutaneouscryoablationforthetreatmentofextraabdominaldesmoidtumors AT leawilliamb percutaneouscryoablationforthetreatmentofextraabdominaldesmoidtumors AT neilsonjohnc percutaneouscryoablationforthetreatmentofextraabdominaldesmoidtumors AT kingdavidm percutaneouscryoablationforthetreatmentofextraabdominaldesmoidtumors AT tuttonseanm percutaneouscryoablationforthetreatmentofextraabdominaldesmoidtumors |